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Cerebral dopamine neurotrophic factor (CDNF) has shown therapeutic potential in
rodent and non-human primate models of Parkinson’s disease by protecting the
dopamine neurons from degeneration and even restoring their phenotype and function.
Previously, neurorestorative efficacy of CDNF in the 6-hydroxydopamine (6-OHDA)
model of Parkinson’s disease as well as diffusion of the protein in the striatum (STR) has
been demonstrated and studied. Here, experiments were performed to characterize
the diffusion and transport of supra-nigral CDNF in non-lesioned rats. We injected
recombinant human CDNF to the substantia nigra (SN) of naïve male Wistar rats and
analyzed the brains 2, 6, and 24 h after injections. We performed immunohistochemical
stainings using an antibody specific to human CDNF and radioactivity measurements
after injecting iodinated CDNF. Unlike the previously reported striatonigral retrograde
transport seen after striatal injection, active anterograde transport of CDNF to the STR
could not be detected after nigral injection. There was, however, clear diffusion of CDNF
to the brain areas surrounding the SN, and CDNF colocalized with tyrosine hydroxylase
(TH)-positive neurons. Overall, our results provide insight on how CDNF injected to the
SN may act in this region of the brain.
Keywords: cerebral dopamine neurotrophic factor, substantia nigra, Parkinson’s disease, striatum, diffusion,
transport
INTRODUCTION
Cerebral dopamine neurotrophic factor (CDNF) is a member of the evolutionarily conserved
group of proteins with its homolog mesencephalic astrocyte-derived neurotrophic factor (MANF)
(Lindholm et al., 2007; Lindholm and Saarma, 2010). In line with expression data from rodents,
CDNF transcript is present in human brain as well as peripheral tissues (Lindholm et al., 2007).
Despite intracellular localization of endogenous CDNF, in vivo data with intracerebral injections of
recombinant human CDNF shows that it can protect dopamine neurons, and more importantly,
restore the functionality of the nigrostriatal dopamine system after toxin-induced degeneration in
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rodent models of Parkinson’s disease (PD) (Lindholm et al.,
2007; Voutilainen et al., 2011; Airavaara et al., 2012). There
is also evidence that CDNF may be involved in endoplasmic
reticulum (ER) stress (Voutilainen et al., 2017). CDNF is a protein
recently used in PD research and tested in phase I-II clinical
trials; it has a structure and a putative mode of action that
is distinct from glial cell-derived neurotrophic factor (GDNF)
and neurturin, as well as other neurotrophic factors. Specifically,
MANF, and also CDNF, have a saposin-like N-terminal domain
which is thought to interact with lipids, and indeed MANF has
been shown to interact with sulfatides (Bai et al., 2018). The
C-terminus of MANF has an α-helical structure (Parkash et al.,
2009) with a cysteine bridge that is similar to other proteins
that function at the ER (Ellgaard and Ruddock, 2005). During
ER stress, the level of MANF is increased and it is able to
bypass the ER-stress induced translational block (Apostolou et al.,
2008), and the same may be happening for CDNF, though this
needs further studies. In general, extracellularly applied protein
and endogenously expressed MANF are likely acting differently
(Matlik et al., 2015; Hao et al., 2017), and in relation to this
study, exogenously administered recombinant CDNF can have a
different mechanism and effects than in its endogenous location.
Radiolabelled CDNF has been shown to be transported to
the substantia nigra (SN) pars compacta within 24 h after an
injection to the striatum (STR) of non-lesioned rats (Voutilainen
et al., 2011). A recent study described the spread and retrograde
transport of CDNF after striatal injection, showing that CDNF
could be detected inside tyrosine hydroxylase (TH)+ neurons
of the SN in non-lesioned rats, but not in 6-hydroxydopamine
(6-OHDA)-lesioned rats where the striatal endings of TH+
neuron fibers were damaged (Matlik et al., 2017). Inside the
striatum, recombinant human CDNF was observed to reside both
extracellularly and in the cytoplasm of striatal neurons (Matlik
et al., 2017). However, it has not been studied whether CDNF




Young adult male Wistar rats (200–250 g) were used in
the experiments. Rats were housed in groups of four in a
12 h light/dark cycle, with ad libitum access to food and
water. All surgeries and behavioral assays were carried out
at the University of Helsinki Laboratory Animal Centre. All
animal experiments were approved by the Finnish National
Board of Animal Experiments (ESAVI/5459/04.10.03/2011 and
ESAVI/7812/04.10.07/2015) and were carried out according
to the European Community guidelines for the use of
experimental animals.
Stereotaxic Surgeries
For CDNF injections, rats were anesthetized with isoflurane (4%
induction, 2.5–3% maintenance) and placed into the stereotaxic
frame (Stoelting). After disinfecting the skin, >0.1 ml of lidocaine
with adrenaline (10 mg/ml, Orion Pharma) was injected under
the scalp. A cut was made along the top of the head to expose the
skull and burr holes were made with a high-speed drill. A 10 µl
Hamilton syringe with a 26G steel needle attached was used to
inject recombinant human CDNF (Biovian Oy, Finland) into
the SN (A/P −5.4, M/L +2.0, D/V −7.2) at a concentration of
0.75 µg/µl. The volume for each injection was 4 µl with a flow
rate of 0.5 µl/min and the needle was left to sit for 5 min after
the injection. Total amount of protein was 3 µg to the SN. For
the diffusion studies in the naïve rat brain, CDNF was injected
to the SN in the same coordinates as above at a volume of 1
or 4 µl and a flow rate of 0.5 µl/min. The amount of protein
in each injection was 3 µg regardless of volume. After stitching
the wound, carprofen (5 mg/kg s.c., Pfizer) was given for post-
operative pain. Rats were placed in a recovery box and then
returned to their home cage upon awakening.
Preparation, Injection, and Analysis of
125I-CDNF
Cerebral dopamine neurotrophic factor (1 µg, Biovian) was
dissolved in 30 µl of 250 mM phosphate buffer, pH 7.5, and 2.7 µl
of carrier-free 125I-Na (5 mCi/14 µl, Perkin Elmer) was added.
First, 5 µl of lactoperoxidase (50 µg/ml, Sigma) was added to start
the reaction. Next, 5 µl of H2O2 was added two times at 10 min
intervals and the reaction mixture was incubated for 20 min at
room temperature. The reaction was stopped with 150 µl of stop
solution (0.1 M phosphate buffer, pH 7.5, containing 0.1 M NaI,
0.42 M NaCl) and 25 µl of 2.5% BSA in PBS. The 125I-labeled
CDNF was separated from free iodine by gel filtration using
Sephadex G-25 columns (PM10; GE Healthcare).
The specific activity for 125I-CDNF was 108 cpm/ug of CDNF
protein and CDNF concentration was 0.5 µg/ml. A bolus of
0.5∗106 cpm of CDNF labeled with 125I was injected (5 ng of
protein in total) as described above, using a 10 µl Hamilton
syringe and a flow rate of 0.5 µl/min into the STR (A/P +1.0,
M/L +2.7 D/V −5.0) or SN (A/P −5.4, M/L +2.0, D/V −7.2)
of adult male Wistar rats. The rats were transcardially perfused
24 h later with PBS to remove the blood. The brain was removed
and dissected immediately after the perfusion. The radioactivity
of the samples was measured on the Wizard 3 1480 Automatic
Gamma Counter (Perkin Elmer, Wallac). Values are expressed
in cpm/mg of wet tissue. For the experiment with unlabelled
CDNF, the injections to the SN were performed as described
above and an additional 10 µg (2000 fold molar excess) or 50 µg
(10 000 fold molar excess) of the unlabelled CDNF protein was
injected to the same location. To calculate the percentage of total
radioactivity, the amount of radioactivity in each dissected brain
area was divided by the summed radioactivity in all brain areas
(total radioactivity). 5–6 rats were used for each experiment.
Tissue Collection and Processing
Two to twenty-four hours after CDNF injections, rats were deeply
anesthetized with a lethal dose of pentobarbital (90 mg/kg, i.p.,
Orion Pharma). They were perfused transcardially with PBS, and
then with 4% paraformaldehyde (PFA). The brains were removed
and placed in 4% PFA overnight, and then transferred to a 20%
sucrose solution and stored in +4◦C. The brains were frozen
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in a cryostat (Leica CM3050) and 40 µm-thick coronal sections
were collected from the whole brain. The sections were collected
into anti-freeze buffer (40% 0.5 M PBS, 30% ethyleneglycol, 30%
glycerol) into sets of six in a 24-well plate.
For the diffusion study, naïve rats injected with CDNF to the
SN were euthanized 2, 6, or 24 h after the injection using the
same perfusion procedure as described above (N = 2/time point).
The brains were removed and embedded in paraffin and cut in
5 µm sagittal sections from 1.40 to 3.40 mm relative to bregma,




For chromagen staining of CDNF, sections were removed from
anti-freeze buffer, rinsed with TBS and then heated in 10 mM
citrate buffer, pH 6, with 0.05% Tween 20 at +80◦C for
30 min. Sections were left to cool at room temperature for
15 min then rinsed with TBS-T (0.1% Tween 20) and blocked
with goat serum (S1000, Vector) in TBS-T (0.015% serum in
TBS-T) for 20 min. The sections were then incubated in the
primary antibody solution (rabbit-anti-human CDNF, 1:500,
stock solution 0.4 mg/mL, Icosagen) overnight at +4◦C. The
next day the sections were incubated in the secondary antibody
solution (goat-anti-rabbit, 1:200, BA1000 Vector) for 1 h and
then transferred into the avidin-biotin complex solution (ABC
kit, Vector) for 30 min and lastly reacted with DAB. The sections
were then rinsed with TBS, put onto glass microscope slides,
dried overnight, dehydrated, mounted and coverslipped with
Coverquick 2000 (Q PATH). Five rats per group were used.
For paraffin sections, after deparaffinization, sections
underwent antigen retrieval by heating them up in citraconic
anhydride (0.05% citraconic anhydride in MilliQ R© water, pH
7.4) without boiling. Slides were then cooled and endogenous
peroxidase activity was quenched using 3% H2O2 in TBS for
30 min at room temperature. Slides were washed with TBS then
sections were encircled with a PAP pen, washed with TBS-T
and blocked with 1.5% normal horse serum (Vector) in TBS-T
for approximately 20 min. The primary antibody (rabbit-anti-
human CDNF, 1:1000, stock solution 0.4 mg/mL, Icosagen) was
then added onto the sections and the slides were incubated at
+4◦C overnight. The next day, the sections were incubated in the
secondary antibody solution (horse-anti-rabbit 1:200, Vector) for
1 hr at room temperature and then in the avidin-biotin complex
solution (ABC kit, Vector) for 30 min. Slides were rinsed with
TBS-T and then the sections were incubated with DAB for 5 min,
rinsed with TBS, dehydrated, mounted, and coverslipped with
Coverquick 2000 (Q PATH).
For fluorescent double staining, the sections underwent
deparaffinization, antigen retrieval and blocking as described
above (except blocking solution used goat serum). The solution
containing the primary antibodies (rabbit-anti-human CDNF,
1:1000, stock solution 0.4 mg/mL, Icosagen, and mouse-anti-
TH, 1:500, Chemicon, MAB318 or mouse-anti-parvalbumin,
1:1000, Merck, MAB1572) was placed on the sections after
which they were incubated at +4◦C overnight. The next day,
the sections were incubated in blocking solution containing
secondary antibodies (goat-anti-rabbit AlexaFluor488, A-11034,
ThermoFischer Scientific, and goat-anti-mouse AlexaFluor568,
A-11004, ThermoFischer Scientific, 1:200) for 2 h at room
temperature. Slides were then washed with TBS-T, briefly with
MilliQ R© water, coverslipped with Vectashield HardSet mounting
medium with DAPI (Vector, H-1500) and after drying briefly at
room temperature stored in+4◦C.
For the confocal images, the fluorescent images stacks were
acquired using the TCS SP5 Confocal Microscope equipped with
LAS AF 1.82 (Leica Microsystems). The objective was Leica
HCX PL APO 63_/1.3 GLYC CORR CS (21◦C). The lasers used
were DPSS 561 nm/20 mW, OPSL 488 nm/270 mW, and diode
405 nm/50 mW, with the beam splitter QD 405/488/561/635. The
images were analyzed with the Leica LAS AF software. A total of 6
rats were used to take representative images from. The number of
puncta inside the cells was analyzed qualitatively from 10 images
taken/rat. This analysis was performed by counting the number
of cells per image that were positive for the CDNF puncta.
Statistical Analysis
Graphs were made in GraphPad Prism 6 (GraphPad Software
Inc.) and statistical analyses were performed in SPSS 22 (IBM).
All results are expressed as the mean ± SEM and considered
to be significant at p < 0.05. P-values are reported from
statistical tests used.
RESULTS
Diffusion of 125I-CDNF After STR or SN
Administration in Naïve Rats
To quantitatively study the diffusion and transport of
intrastriatally injected CDNF to other brain areas, and to
repeat our previously published data (Voutilainen et al., 2011),
as well as have a positive control, 125I-labeled CDNF was injected
to the STR of rats, and 24 h later dissected brain areas were
measured in a gamma counter (Figures 1A,B). CDNF spread
intensely to the frontal cortex of the injected side, while there
was little spread of 125I-CDNF to other cortical areas. CDNF also
spread well to the ipsilateral and contralateral hippocampus, and
SN (Figures 1A,B).
Next, we wanted to analyze CDNF diffusion after nigral
administration and possible anterograde transport from SN to
STR which has not been studied before. CDNF labeled with 125I
was injected into the SN of rats and brain areas dissected 24 h
later were measured on a gamma counter (Figures 1C,D). CDNF
diffused most strongly to the ipsilateral subthalamic nucleus
(STN) from the SN. The radioactivity in the ipsilateral SN was
the highest overall, with it being significantly different than
the other brain areas (excluding the STN) [One-way ANOVA,
F(11,52) = 8.6, p = < 0.0001] (Figure 1C).
To study whether the spread of CDNF to the STN was due
to passive diffusion or active transport mechanisms, 125I-CDNF
was administered to the SN together with two doses of unlabelled
CDNF (2000 fold molar excess or 10 000 fold molar excess) to
compete for binding and active axonal transport of the labeled
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FIGURE 1 | Diffusion of 125 I CDNF when injected to the STR or SN of naive rats. (A,B) Percentage of the total radioactivity (calculated based on radioactivity of all
brain areas measured) after injecting radiolabeled CDNF (125 I-CDNF) into the STR of naive rats and measuring 24 h later, ipsilateral regions (A) and contralateral (B).
(C,D) Percentage of the total radioactivity (calculated based on radioactivity of all brain areas measured) after injecting radiolabeled CDNF into the SN of naive rats
and measuring 24 h later, ipsilateral regions (C) and contralateral (D). (E,F) 2000× or 10 000× molar excess of cold (unlabeled) CDNF was given together with
radiolabeled CDNF to SN of naive rats and measured 24h later. Ipsilateral regions (E) and contralateral (F). (n = 5–6/brain region) Bars represent mean ± SEM.
∗∗∗∗p = < 0.0001. FCTX, frontal cortex; CTX, cortex; STR, striatum; HC, hippocampus; SN, substantia nigra; GP, globus pallidus; STN, subthalamic nucleus.
CDNF. The diffusion/transport of 125I-CDNF from the SN to the
STN was not blocked by either of the doses of unlabelled CDNF
[One-way ANOVA, F(2,18) = 0.0068, low: p = 0.9801, df = 52;
high: p = 0.9928, df = 52] (Figure 1E) which suggests passive
diffusion of CDNF after nigral administration.
Diffusion of Unlabelled CDNF Protein in
the Naïve Rat Brain After Nigral
Administration
When CDNF protein was injected to the SN of the naïve rat brain
and monitored at different time points in order to characterize
the diffusion after nigral injection, we observed robust CDNF
staining in the ipsilateral midbrain including the SN at the 2
(Figure 2A) and 6 (Figure 2B) hour time points, but not at
the 24 h time point (Figure 2C). Additionally, CDNF protein
appeared to diffuse anteriorly and posteriorly from the SN at 2
and 6 h, but again was not detected at 24 h. At the 2 and 6 h
time points, there was clear staining in the hippocampus and
amygdala, as well as thalamic and hypothalamic regions. There
was no staining observed in the dorsal STR at any of the time
points. As this was a qualitative experiment, two rats were used
per time point and the staining was similar in both.
Additionally, increasing the volume of the CDNF injection
while keeping the total amount of protein constant, increased its
diffusion in the SN. When 1 or 4 µl of CDNF was injected to the
SN of naïve rats, the higher volume appeared to diffuse farther
after 2 h as compared to the lower volume (Figure 2D). It can also
be observed that at higher magnifications there are concentrated,
darkly stained puncta throughout the injected area (Figure 2E,
black arrowheads).
CDNF Colocalizes With TH+ Neurons
and Is Diffused Around the Nigral Area
As shown above (Figure 2A), 2 h after the injection to the
SN CDNF staining is present in the nigral area. Next, we
wanted to determine whether CDNF colocalized with TH+
neurons or parvalbumin (PV) neurons using immunofluorescent
staining and confocal microscopy. Brains from six rats were
analyzed to clarify whether CDNF colocalized with either of
the neuronal subtypes. Out of several cells detected in the
nigral area of each brain, it could be observed that there
were CDNF immunoreactive puncta (cyan, white arrows) inside
approximately two thirds of the TH+ neurons (magenta,
Figure 3A) on the injected side. In contrast, out of several
cells observed in the PV stained sections, CDNF was diffused
around the neurons but did not appear to colocalize with them
(Figure 3B), since only approximately one tenth of the PV+
cells had immunoreactive puncta present. Additionally, as can be
clearly observed in Figure 2, there is diffuse CDNF staining all
around the midbrain/SN. The confocal images show the same:
CDNF is diffused around the cells and only some cells have
CDNF-immunoreactive puncta.
DISCUSSION
We showed that radiolabelled CDNF injected into the SN was
not transported to the STR or other brain areas, whereas striatally
injected CDNF was transported to SN, hippocampus, and frontal
cortical areas as shown earlier by Voutilainen et al. (2011).
Instead, CDNF readily diffused in the brainstem/midbrain, in
particular around the SN, to the hippocampus, and amygdala
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FIGURE 2 | Diffusion of human CDNF after injection to the SN in naive rat brain at different time points and volumes. CDNF (3 µg in 4 µl) was injected to the SN of
rats and perfused (A) 2, (B) 6, or (C) 24 h later. Human CDNF (hCDNF) immunostaining of a representative posterior, nigral, thalamic, and striatal section for each
time point. N = 2/time point. Diffusion of human CDNF (3 µg) when injected into the SN in the volume of 1 or 4 µl. Rats were perfused 2 h after the injection.
(D) Increasing magnification of CDNF injected side versus the uninjected side of the injected area. (E) 40× maginification of injected area. Black arrowheads indicate
dark brown puncta staining of CDNF.
within 2 to 6 h after the nigral injection. Additionally, CDNF
colocalized with TH+ neurons in the SN, indicating it was likely
taken up by these neurons.
Since diffusion and transport of CDNF after striatal injection
has been studied previously, we wanted to investigate the
diffusion of CDNF after nigral injection. Using radiolabelled
CDNF we observed the spread of the protein to distinct brain
regions. As shown earlier by Voutilainen et al. (2011), when
injected to the STR, CDNF spread to the cortex, both sides of the
STR, and the hippocampus. There is also clear evidence of CDNF
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FIGURE 3 | Representative confocal images of CDNF-injected rat substantia nigra with tyrosine hydroxylase (TH) neurons or parvalbumin (PV) neurons to
demonstrate colocalization. (A) Representative confocal images from a rat brain injected with human CDNF into the substantia nigra (SN) and perfused 2 h later with
costaining for CDNF and TH. Total of six rats were injected and stained for the colocalization study. White arrows in the injected side indicate CDNF immunoreactive
puncta (cyan dots). Uninjected side representative image taken with identical settings to account for possible background. Top panel 10× objective, lower panel 63×
objective. (B) Representative confocal images from rats injected with human CDNF into the SN and perfused 2 h later with costaining for CDNF and PV. Uninjected
side representive image taken with identical settings to account for possible background. Top panels 10× objective, lower panels 63× objective. N = 6.
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transported to the SN after striatal injection (Voutilainen et al.,
2011; Matlik et al., 2017). After injection of radiolabelled CDNF
to the SN, it remained in the ipsilateral side and only diffused as
far as the STN. CDNF did not seem to be transported or diffused
to the STR. This is in line with the immunohistochemistry data
obtained here. When unlabelled protein was used to block the
transport of radiolabelled CDNF after nigral injection, neither
the 2000 nor the 10 000 molar excess of unlabelled protein
could block the diffusion of CDNF to the STN. Therefore, we
can conclude that CDNF is not undergoing active transport, but
rather passive diffusion after nigral administration. Interestingly,
only radiolabelled CDNF was present in the brain regions 24 h
after the injection. The discrepancy between the radioactivity
measurements and the immunohistochemistry results could be
due to the limit of detection for the antibody used. In other words,
though the CDNF antibody is able to detect the injected human
CDNF specifically, it may be that it has diffused significantly
or degraded by this time point, and was not visible by eye or
microscope in the immunostained brains.
Since radiolabelled CDNF is detected significantly in the
STN of the brains, it seems that it is diffusing to this area,
and is not transported, as indicated from the blocking study.
Nonetheless, there is the possibility that CDNF was taken up
by glutamate terminals of the SN reticulate and transported
to the STN (Robledo and Feger, 1990; Parent and Hazrati,
1995). Although this was not studied here, future studies could
examine the potential uptake and effects of CDNF at the STN,
which might be critical for the biological effects of extracellularly
administered CDNF.
The same phenomenon observed in the current study is
also occurring when GDNF, a neurotrophic factor with known
transmembrane receptor GFRalpha1/RET, is administered to the
STR or SN. After striatal delivery, GDNF is transported to the
SN whereas with nigral delivery it diffuses in the SN area as well
as the hippocampus but is not transported to the STR (Kearns
and Gash, 1995; Tomac et al., 1995). This then begs the question
why are these proteins being transported to the SN from STR
but not vice versa when it has been demonstrated that in other
contexts molecules are transported from SN to STR (Hattori et al.,
1973). Instead, CDNF may undergo lysosomal degradation when
injected near the cell bodies, instead of axonal transport as is the
case with nerve growth factor (Butowt and von Bartheld, 2009).
When recombinant human CDNF was injected to the SN of
naïve rats, it was detected widely in the midbrain areas after 2
and 6 h, but not at 24 h post-injection. This could indicate that
the protein was cleared away between 7 and 24 h, or that it is
diffusing significantly and therefore is at a lower concentration
which could not be detected anymore using immunostaining.
Since the half-life of CDNF is 5.5 h after striatal injection (Matlik
et al., 2017), this is expected. In the representative sagittal images
of the CDNF staining in paraffin sections, CDNF appears to
diffuse farther with a larger volume though the protein amount
is the same. These results indicate the importance of volume in
CDNF’s diffusion, where a higher volume may lead to the protein
itself reaching a more distant area to exert its effects, even if the
concentration is lower. This has also been observed with GDNF
(Taylor et al., 2013).
Lastly, when the midbrain sections were co-stained for CDNF
and TH/PV, we observed that CDNF did colocalize with TH
positive neurons in the SN, while the colocalization with PV
positive neurons was less evident. Colocalization with TH-
expressing cells in the SN was also observed by Matlik et al.
(2017). They showed CDNF to be present in the TH+ neurons
6 h after striatal injection. PV neurons present in the SN
(Gerfen et al., 1985), of which most are GABAergic inhibitory
neurons (Lee and Tepper, 2007), were chosen as another neuron
subtype for colocalization due to their putative involvement in
sensorimotor functions and motor integration (Bernacer et al.,
2012), which are important for PD. Based on our results, it
appears that CDNF is not colocalizing with PV+ neurons in the
SN. Thus, CDNF may exert its effects at the cell surface since it is
present around the cells. Since the colocalization of CDNF with
different neuronal subtypes was assessed only qualitatively here,
further analyses are needed to draw decisive conclusions.
The diffusion of CDNF after injection to the SN was studied
here for the first time. We observed clear diffusion of CDNF to
the STN and the brainstem areas around the SN, but no transport
to the dorsal STR. Interestingly, we observed colocalization of
CDNF with TH+ neurons, but less so with PV+ neurons, in the
SN. Knowing the optimal site of administration and diffusion
or transportation properties of a neurotrophic treatment is of
paramount importance in developing new disease-modifying
therapies for PD where the normal neuroanatomical connections
are lost due to degenerating dopamine neurons.
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